Saturday, April 1, 2023
News
NEWS HOME
»
PRN INDIA
Stemline Therapeutics, a subsidiary of Menarini Group, Receives U.S. FDA Approval for ORSERDUTM (elacestrant) as the First and Only Treatment Specifically Indicated for Patients with ESR1 Mutations in ER+, HER2- Advanced or Metastatic Breast Cancer
  SocialTwist Tell-a-Friend  
   

  • ESR1 mutations are present in up to 40% of ER+, HER2- advanced or metastatic breast cancers.
  • ESR1 mutations are a known driver of resistance to standard endocrine therapy, and so far, have been difficult to treat.
  • ORSERDU is the first endocrine innovation in more than 20 years, specifically addressing ESR1 mutations, a major unmet need.

FLORENCE, Italy and NEW YORK, Jan. 30, 2023 /PRNewswire/ -- The Menarini Group ("Menarini"), a leading Italian pharmaceutical and diagnostics company, announced today that the U.S. Food and Drug Administration (FDA) has approved  ORSERDU for the treatment of postmenopausal women or adult men, with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy. Stemline Therapeutics ("Stemline"), a wholly-owned subsidiary of the Menarini Group, headquartered in New York and focused on bringing transformational oncology treatments for cancer patients, will commercialize ORSERDU in the U.S.

Menarini Group Logo

"The FDA approval of ORSERDU marks the first ever therapy for ER+, HER2- advanced or metastatic breast cancer patients with ESR1 mutations and we are very proud to offer a targeted therapy addressing this huge unmet need," commented Elcin Barker Ergun, Chief Executive Officer of the Menarini Group. "We are grateful to the patients, investigators and administrators who participated in the clinical trials that led to this remarkable innovation."

ORSERDU is approved under the FDA's Priority Review and Fast Track designation based on the results of the registrational Phase III trial EMERALD, that demonstrated statistically significant progression-free survival (PFS) with elacestrant vs SOC endocrine monotherapy (fulvestrant, letrozole, anastrozole, exemestane), meeting both primary endpoints in all patients and in those patients whose tumors harbor ESR1 mutations.

In the group of patients whose tumors had ESR1 mutations, elacestrant reduced the risk of progression or death by 45% (PFS HR=0.55, 95% CI: 0.39, 0.77) vs SOC. A post-hoc analysis of the PFS results based on the duration of prior CDK4/6i inhibitors (CDK4/6i) usage was presented at San Antonio Breast Cancer Symposium (SABCS) in December 2022. The median PFS was 8.6 months on elacestrant vs 1.9 months for SOC, in those patients whose tumors harbored ESR1 mutations and had been treated with a CDK4/6i for at least 12 months.

Safety data is consistent with the other endocrine therapies. Most of the adverse events (AEs), including nausea and musculoskeletal pain were grade 1 and 2. No hematological safety signal was observed and none of the patients in either of the two treatment arms had sinus bradycardia.

"Advanced or metastatic ER+, HER2- breast cancer pre-treated with endocrine-based therapy remains an area of unmet medical need. The last endocrine therapy approved was about 20 years ago, and effective endocrine options for this patient population are needed," said Dr. Aditya Bardia, MD, MPH, Director of Breast Cancer Research at Mass General Cancer Center, Associate Professor at the Medicine Department at Harvard Medical School, and Principal Investigator for the EMERALD trial. "ESR1 mutations are a known driver of resistance to standard endocrine therapy, and so far, have been difficult to treat. The approval of elacestrant is welcomed as it offers a novel option for patients with ER+, HER2- metastatic breast cancer. This therapy targets the ESR1 mutations in metastatic breast cancer and provides patients with a convenient oral once-daily dose."

"Each year 300,000 Americans are diagnosed with breast cancer and metastatic breast cancer causes  the vast majority of  deaths from the disease: more than 43,000 annually. We urgently need new and better treatment options to extend and improve the lives of people with metastatic breast cancer," said Sonya Negley, Executive Director, Metavivor. "We are thrilled to see the approval of ORSERDU, a new oral endocrine therapy, for patients who have tumors that harbor ESR1 mutations, which are present in up to 40% of ER+, HER2- advanced or metastatic breast cancer. We advise patients to get tested for ESR1 mutations  at progression in their metastatic treatment, so that their healthcare team can identify the right treatment options for their disease."

ORSERDU  will soon be available in the United States.  Stemline is committed to helping patients access ORSERDU  and will be offering services to overcome access barriers.  Stemline ARC, a patient support program is available to help guide eligible patients through the various aspects of getting started on treatment, from providing educational information to helping them understand their insurance coverage and identify potential financial assistance options. For more information, patients and healthcare professionals can call 1-833-4-STEMLINE (1-833-478-3654)

The Menarini Group obtained global licensing rights for elacestrant in July 2020 from Radius Health, Inc., who conducted the EMERALD study.   With this approval, Radius will receive milestone payments and royalties from commercial sales. The Menarini Group is now fully responsible for global registration, commercialization, and further development activities for elacestrant.

About EMERALD Phase 3 Study (NCT03778931)
The EMERALD Phase 3 trial is a randomized, open label, active-controlled study evaluating elacestrant as second- or third-line monotherapy in ER+, HER2- advanced/metastatic breast cancer patients. The study enrolled 478 patients who had received prior treatment with one or two lines of endocrine therapy, including a CDK4/6 inhibitor. Patients in the study were randomized to receive either elacestrant or the investigator's choice of an approved hormonal agent. The primary endpoints of the study were progression-free survival (PFS) in the overall patient population and in patients with estrogen receptor 1 gene (ESR1) mutations.

About ORSERDU (elacestrant)
The U.S. Food and Drug Administration (FDA) has approved  ORSERDU for the treatment of postmenopausal women or adult men, with ER+, HER2-, ESR1-mutated, advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy. The Marketing Authorization Application (MAA) is currently under review by the European Medicines Agency (EMA).

Elacestrant is also being investigated in several clinical trials in metastatic breast cancer disease, alone or in combination with other therapies: ELEVATE (NCT05563220); ELECTRA (NCT05386108); ELONA (NCT05618613); ELCIN (NCT05596409). Elacestrant is also planned to be evaluated in early breast cancer disease.

Full prescribing information can be found at www.orserdu.com

Important Safety Information

Warning and Precautions

Dyslipidemia: Hypercholesterolemia and hypertriglyceridemia occurred in patients taking ORSERDU at an incidence of 30% and 27%, respectively. The incidence of Grade 3 and 4 hypercholesterolemia and hypertriglyceridemia were 0.9% and 2.2%, respectively.   Monitor lipid profile prior to starting and periodically while taking ORSERDU.

Embryo-Fetal Toxicity: Based on findings in animals and its mechanism of action, ORSERDU can cause fetal harm when administered to a pregnant woman.   Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with ORSERDU and for 1 week after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with ORSERDU and for 1 week after the final dose.

Adverse Reactions

Serious adverse reactions occurred in 12% of patients who received ORSERDU. Serious adverse reactions in >1% of patients who received ORSERDU were musculoskeletal pain (1.7%) and nausea (1.3%). Fatal adverse reactions occurred in 1.7% of patients who received ORSERDU, including cardiac arrest, septic shock, diverticulitis, and unknown cause (one patient each).

The most common adverse reactions (>10%), including laboratory abnormalities, of ORSERDU were musculoskeletal pain (41%), nausea (35%), increased cholesterol (30%), increased AST (29%), increased triglycerides (27%), fatigue (26%), decreased hemoglobin (26%), vomiting (19%), increased ALT (17%), decreased sodium (16%), increased creatinine (16%), decreased appetite(15%), diarrhea(13%), headache (12%), constipation (12%), abdominal pain (11%), hot flush (11%), and dyspepsia (10%).

Drug interactions

Concomitant use with CYP3A4 Inducers and/or inhibitors:   Avoid concomitant use of strong or moderate CYP3A4 inhibitors with ORSERDU. Avoid concomitant use of strong or moderate CYP3A4 inducers with ORSERDU.

Use in specific populations

Lactation: Advise lactating women to not breastfeed during treatment with ORSERDU and for 1 week after the last dose.

Hepatic Impairment: Avoid use of ORSERDU in patients with severe hepatic impairment (Child-Pugh C). Reduce the dose of ORSERDU in patients with moderate hepatic impairment (Child-Pugh B).

The safety and effectiveness of ORSERDU in pediatric patients have not been established.

To report SUSPECTED ADVERSE REACTIONS, contact Stemline Therapeutics, Inc. at  1-877-332-7961 or FDA at  1-800-FDA-1088  or  www.fda.gov/medwatch.

Indication
ORSERDU (elacestrant), 345 mg tablets, is indicated for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.

For more information, please see the full Prescribing Information for ORSERDU here

About The Menarini Group
The Menarini Group is a leading international pharmaceutical and diagnostics company, with a turnover of over $4 billion and over 17,000 employees. Menarini is focused on therapeutic areas with high unmet needs with products for cardiology, oncology, pneumology, gastroenterology, infectious diseases, diabetology, inflammation, and analgesia. With 18 production sites and 9 Research and Development centers, Menarini's products are available in 140 countries worldwide. For further information, please visit www.menarini.com.

About Stemline
Stemline Therapeutics, a wholly-owned subsidiary of the Menarini Group, is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics. Stemline commercializes Elzonris ®, a novel targeted treatment directed to CD123 for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare hematologic cancer, in the United States and Europe, the only approved treatment for BPDCN in the US and EU to date. Stemline also commercializes Nexpovio ® in Europe, an XPO1 inhibitor for multiple myeloma originating from a licensing deal with Karyopharm. Stemline has an extensive clinical pipeline of small molecules and biologics in various stages of development for a host of solid and hematologic cancers.

Logo - https://mma.prnewswire.com/media/1958938/MENARINI_GROUP_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/stemline-therapeutics-a-subsidiary-of-menarini-group-receives-us-fda-approval-for-orserdutm-elacestrant-as-the-first-and-only-treatment-specifically-indicated-for-patients-with-esr1-mutations-in-er-her2--advanced-or-metast-301733294.html

More News by PR Newswire India

CGTN: 50 years on, China, Spain have profound friendship, achieve common prosperity

CGTN: China, Singapore upgrade relations for higher-quality cooperation

The INX Digital Company Reports Q4 2022 Update and Annual Financial Results

Venturi Astrolab's FLEX rover to launch to the Moon on an upcoming SpaceX mission

GS1 UK appoints Syndigo to enhance productDNA data management and sharing service

Stratasys announces channel partnership with Adroitec Information Systems Pvt. Ltd.

Roll1ng Thund3rz launches WEB3WAR - a blockchain-secured first-person shooter

Taiwan's President Visits U.S., Central America: TaiwanPlus Coverage to Feature Exclusive Interviews

Polaris® Cuts the Cord

Appointment of Independent Director on the Board of Azure Power Global Limited

Zones Expands IT Service Delivery Footprint in India

HarperCollins Publisher Launches 'Swayam ki Awaaz: How to Find Peace in a Noisy World' by World-renowned Educator and Bestselling Author Prem Rawat

Tianlong Announces Global Release of GeneFlex Nucleic Acid Extractor and Gentier mini+ Real-time PCR System

Chandigarh University makes a stellar debut in 5 Subjects in QS World University Subject Rankings 2023

Howzat rolls out its Indian T20 campaign 'The Grand Winnings Playground' with prizes worth â‚ą600 crores

ANUJA CHAUHAN IS BACK WITH A THRILLING NEW WHODUNNIT, A SEQUEL TO THE SOON-TO-BE-A-MOVIE MURDER MYSTERY, CLUB YOU TO DEATH, FEATURING THE BELOVED DETECTIVE, ACP BHAVANI SINGH

Xiaomi Presents its Customer Success Solutions with Xapads at the Game Developers Conference

Flamingo Transworld Takes User Experience to New Heights With A Website Makeover

CGTN: China's certainty is a mainstay of world peace, development: premier

ACCEPTANCE PERIOD EXTENDED PENDING INDIAN COMPETITION CLEARANCE UNTIL NO LATER THAN 12 MAY 2023

Koo Promises Lifetime Free Verification for all Notable Personalities

Team of Doctors at Sahyadri Hospital perform 'Zero contrast angioplasty' - a boon to kidney patients

nStore announces its Partnership with Monginis

WIZ.AI launches TalkGPT, ASEAN's first ChatGPT-powered customer engagement solution for business

MIT Technology Review Insights' Green Future Index 2023 third annual ranking sees progress wavering as atmospheric carbon levels soar

NADclinic Group, BioStarks and Do Not Age Announce Exclusive Partnership to Revolutionise Personalised Longevity

ViewSonic Targets to Double its Monitors Business for Hybrid Workspace

Croma-Pharma: Further strengthening its portfolio with PhilArt biostimulators

Arctech Harvests Largest Solar Project in Azerbaijan

UNDER ARMOUR AND STEPHEN CURRY ENTER LONG-TERM PARTNERSHIP

GC Creates Innovation For a Better Quality of Life for the World, Using High-quality Recycled Plastic Resins of Food Grade Level Guaranteed Safe by FDA

Sung Hwan Cho of Hyundai Mobis at the 44th Vienna International Motor Symposium

Huawei and bKash Strengthen Partnership to Deepen Financial Inclusion in Bangladesh to Support the SDGs

Pexpo launches sustainable water bottles, commits to 'Health on the Go'

Inside the Action: A Toshiba TV Offering to Gamers

HistoSonics Announces First Ever Kidney Tumor Treatment Using Histotripsy

Lacework Celebrates Inspiring "Secured by Women" Leaders

IMG Travel Outlook Survey Predicts Continued Surge of International Travel in 2023

LEVI'S® EXPANDS RETAIL FOOTPRINT IN ASIA, ANNOUNCES OPENING OF REGION'S LARGEST STORE IN BENGALURU, INDIA

48-year old doctor from Islampur undergoes three surgeries in a single setting

Onfido Applauded by Frost & Sullivan for Enhancing Identity Verification and Customer Experience with Its Robust Digital Identity Verification Platform

Pixalate Releases February 2023 Mobile Device Global Market Share Report: Apple iPhone Reaches 72% North American Programmatic Advertising Market

PartnerOne Completes the Acquisition of Stromasys

PacketFabric and Unitas Global Complete Merger

Results Revealed: 2022 PHBS-CJBS Global Pitch Competition Held in Shenzhen

MYEG Signs Agreement with China Customs for Cross-Border Trade Connectivity on Zetrix Blockchain Platform

Upgrade Skills with Mediflick's Effective and Affordable Medical Courses

Industry players call for a 'non-stop' approach to Africa's banking digitisation

BitKeep Rebrands As Bitget Wallet After Acquisition

Timex Becomes the Official Timekeeper of Gujarat Titans

TCL Takes the Top 2 TV Brand Spot Globally by Making Mini LED Technology Accessible to Millions

BasaltCoin: One of the Most Promising Projects Successfully Launched on March 26, 2023

BAE Systems and Heart Aerospace to collaborate on battery for electric airplane

ID Tech partners with MCD to Provide Complete Traceability, Transparency and Visibility for Solid Waste Management and remediation of waste dumps in Delhi

Hexaware Named Among The Economic Times Best Organisations for Women 2023

ECOVACS Group celebrates 25 Years with industry-leading innovations

CGI is Great Place to Work-certified™ in India

This Summer, Platinum Guild International (PGI) India, offers a stunning collection of platinum jewellery by PLATINUM EVARA

Black & White Ginger Ale by Diageo Sets Up A 'Table for Everyone' - Encourages Varied Perspectives, Fosters Inclusion, Ignites Meaningful Conversations

Dow Launches New Digital Coatings Formulation Platform: Paint Vision

Vymo recognized in the 2023 Gartner® Market Guide for Sales Engagement Applications

CDNetworks and VSTV K+ Partner to Elevate the Experience of Premium OTT Services in Vietnam

Zimmer Biomet's ROSA HIP with ONE Planner Hip Awarded Orthopaedic Product Innovation of the Year by Healthcare Asia Medtech Awards 2023

Prime Focus Technologies launches CLEAR® AI Reframe and enhances CLEAR® AI Discover with Chat GPT

Axi extends multi-year partnership deal with Man City

Hevo Data Strengthens Data Integration Offering with Google Cloud Ready - BigQuery Designation

ProWein 2023: Wine of Moldova Commits to Go Sustainable

Adriel to Power AdOps Marketing Solution for LG Electronics

Tony Robbins To Close the Global PRIORITY Summit Held by FII Institute

Continuous evolution key to successful organizational transformation, says MIT Technology Review Insights report

AlgoKit Introduces Web2 Developer Experience for Building Web3 Applications on Algorand

Neo4j and Google Cloud Extend Strategic Partnership With New Native Integration to Google Cloud's BigQuery Cloud Data Warehouse

Starburst Achieves Google Cloud Ready - BigQuery Designation

IMA Student Leadership Conference in New Delhi Focuses on Engaging Gen Z on the Future of Finance

TO CELEBRATE THIS SUMMER WEDDING SEASON, PLATINUM GUILD INTERNATIONAL (PGI), INDIA, OFFERS STUNNING PLATINUM LOVE BANDS BY PLATINUM DAYS OF LOVE

Sai Life Sciences and NIIT Foundation partner to create livelihood opportunities for underserved communities in Hyderabad

This summer, Platinum Guild International (PGI), India launches an exclusive collection of statement pieces from Men of Platinum

Accops recognized in the 2023 Gartner® Market Guide for Desktop as a Service

BitKeep 2023 Roadmap Reveals Its Plan to Rebrand as Bitget Wallet and Strengthen Security

The Passport Index points to declining fortunes for Asian superpowers India and China

Great Place To Work India and HDFC ERGO come together to drive the movement of 'Making India a Healthy Place to Work For All'

NetEase announces "Lord of the Rings" Game Fanfiction Contest

Shoolini Engineering Earns High SCImago Rankings

Advertising legend Raj Kamble is the only Indian Nominee at Campaign's Global Agency of the Year Awards 2023 list

MIT Technology Review Examines the Emergent Industrial Metaverse with Siemens AG

BRITISH VIRGIN ISLANDS COMPANIES SUPPORT 2.3M JOBS AND GENERATE US$14BN IN TAX REVENUES GLOBALLY

Teleperformance launches its futuristic new site in Hyderabad

A Resolution through Farmer's Training on the Water Crisis Management in Agrarian India

E Ink Teams up with Indian Tech OEM SuperUs to Drive Localization in India

Valuebound Attains AWS Advanced Consulting Partner Status, Offering Expert Cloud Migration Services

SafeHouse Tech launches SafetyScore to assess user's safety online

Mentoria Partners with Governments and Foundations to Make India #CareerReady

People in Asia seek to extend health span for longer, healthier retirement, Manulife survey shows

Omdia: Samsung leads while BOE increases small medium AMOLED shipment market share in 2022

BMO Recommends Shareholders Reject TRC Capital's Below-Market "Mini-Tender" Offer

APPTIO INDIA LLP Is Great Place to Work Certified for Second Year

BETT 2023: ViewSonic to Debut Expanded EdTech Solutions Across UNIVERSE Virtual Campus and myViewBoard Ecosystem

LE DU IN BANGKOK CLAIMS NO.1 SPOT AT ASIA'S 50 BEST RESTAURANTS 2023

MNCs View CIIE as Launch Pad into Chinese Market

Kivu Consulting, Inc. announces strategic partnership with Microsoft

Argentina's Minister of Economy Sergio Tomás Massa and Top Silicon Valley Investors Marc Andreessen and Ben Horowitz to Speak at PRIORITY, Powered by FII Institute

Kixx Aims to Become Top Lubricant Brand Around the World, Highlighting Its Advanced Industrial Lubricants

Movable Ink Launches New Mobile Suite to Help Brands Worldwide Better Engage Customers on Their Channel of Choice

BIMINI HEALTH TECH ACQUIRES EXCLUSIVE LICENSE TO ACELLULAR DERMAL MATRIX PRODUCT PORTFOLIO

VCTI Announces Appointment of Scott Widham to Board of Directors

Lacework Marries its Global Partner Ecosystem with the Cloud Security Needs of Customers

Sennheiser Profile USB microphone provides ease of use and best-in-class audio

IBM Brings Generative AI Commentary and Hole-by-Hole Player Predictions to the Masters Digital Experience

Kohler Presents 'The Creator's Journey' at Milan Design Week

Omega Seiki Mobility (OSM) partners with cKers Finance to provide retail finance for electric three wheelers

AV-Comparatives awarded best-performing IT security software at Hasegg Castle / Royal Mint in Hall, Tyrol

Colgate-Palmolive promotes 'Innovation in Oral Health' in association with Indian Dental Association

Allstate India Named One of India's 40 Best Workplaces in Health and Wellness 2022 by Great Place to Work® Institute

Yokogawa Releases OpreX Asset Health Insights with Enhanced Functionality and Alibaba Cloud Support

STL's optical products testing labs rated highest on stringent quality standards set by NABL and TEC

2023 Africa Wealth Report Reveals 'Big 5' Host 56% of Continent's Millionaires

Scharf Investments Global Equity Strategy Awarded Mandate from a Key Nordic Pension Fund

Medanta Gurugram recognized as the Best Private Hospital in India Fourth Time in a Row

Hexaware's Vikash Jain Honored at ASSOCHAM Vibrant Bharat CFO Summit & Awards and CFO100 2023 Programme for Outstanding Financial Leadership

VdoCipher Video Player Powers 3,000+ Platforms across 120+ Countries

UST's CSR Initiatives Recognised at 2023 KMA Awards

Amway Applauded by Frost & Sullivan for Capitalizing on Innovative Competitive Strategies to Drive Differentiation in Its Home Water Treatment Solution in APAC

Colliers expands capital markets & investment business across asset classes

PR Newswire Sees 7% Growth in Asia-Pacific Release Distribution

QSnatch infections are the leading cause of malicious DNS traffic in Asia Pacific, according to latest findings by Akamai

KPG Roofings Opens Its First roof tile Showroom in Hyderabad and 40th showroom in India

Otr Elkalam: In the world's largest religious competition - A Saudi Opera Singer Eliminates a Voice Coach

The Organizing Committee of Memorial Ceremony to Ancestor Huang Di in his Native Place Held its Press Conference in Beijing

Aramco to expand presence in China by acquiring 10% stake in Rongsheng Petrochemical

BNI® TO HELP ITS MEMBERS DOUBLE VALUE OF THEIR BUSINESS

Syndigo Announces Additional Generative AI Capabilities to its Client Platform

2026 All-Time High in Store for Global 300mm Semiconductor Fab Capacity After 2023 Slowdown, SEMI Reports

Tata Communications brings JAMVEE™ - an integrated, simplified cloud-based calling solution for global enterprises

38th Annual World Petrochemical Conference: Wanhua Chemical Shares Inspiring and Insightful Practice on Sustainability in Petrochemical Industry

CONNECTING BUYERS, SELLERS TO $1 TRILLION M&A MARKET WITH NEW DEAL DISCOVERY SaaS SOLUTION

Shipping industry can save $50 bn through four enablers of operational efficiency

LyondellBasell and EEW sign LOI for potential advanced waste sorting

Armis Achieves U.S. Department of Defense Impact Level 4 Authorization

The Second International Forum on "Democracy: The Shared Human Values" kicked off in Beijing

Bitget Becomes the First Centralized Exchange to Offer Financial Transparency Through Space and Time

Forever New Launches Exquisite SS23 Collection Featuring Pooja Hegde

Transparent & good governance, inclusive Growth and opportunities for all mark the emergence of New India under the leadership of PM Narendra Modi says Union MoS Rajeev Chandrasekhar

Inkspell set to organize the Video Media (vIdea) Awards & Summit 2023 on 27th April

Indian Low-voltage Switchgear Market Witnesses Surge Due to Pent-up Demand and an Increase in the Average Price

Aramco JV HAPCO to commence construction of major refinery and petrochemical complex in China

GCL System Integration Brings N-Type Innovation TOPCon and Latest BIPV Products to PV EXPO 2023

Aditi Mittal, Director at IndiaBonds and A. K. Group wins Times 40 Under 40 Award

Beamery Announces TalentGPT, the World's First Generative AI for HR

Appian appoints Douglas Coleman as Head of Mexico

Measure the Impact of Mantras on the Brain with the Sadhana app

International Aluminium Institute launches Aluminium Forward 2030 Coalition

Bharat KYC secures 'Fastest eKYC' and QuantPower bags 'Best Algo Trading Platform' Award from NITI Ayog Advisor & Bollywood Diva Bhagyashree

Transcoding and Content Security Workflow Simplified: INKA Entworks's PallyCon and Dolby Hybrik Join Hands for an Integrated Solution

ESG practices towards transformative change for a more sustainable world

Making Open Source Truly Open

The 3rd Conference of Great Business Partners to be held in Shandong

New Cryptocurrency BASALTCOIN set to Launch with a Mission to Revolutionize the Greentech Industry

CGTN: How China keeps its promise to build a community of common health for mankind

CGTN: Analysis: China's economic resilience boosts global recovery prospects

YourStory's TechSparks makes thundering debut in Mumbai: A two-day gala featuring India's top entrepreneurs, investors, innovators, and more

 
 
TRENDING TOPICS
 
 
CITY NEWS
MORE CITIES
 
 
INDIA WORLD ASIA
4 arrested for smuggling country liquor ...
ED attaches assets of former Assam govt ...
4.0 magnitude earthquake hits Andaman an...
Bihar announces subsidy of Rs 13,114 cro...
US Consulate, USAID fund beauty salon ru...
14 injured after two groups clash in Bih...
More...    
 
 Top Stories
Farmers of Pema Gatshel district of... 
US weapons left behind in Afghanist... 
Interest rate on small savings sche... 
Local employees ill-treated by Chin... 
Win against Kyrgyz Republic could s... 
White House says won't pay for staf... 
Ampere Electric Two-wheeler registe... 
Bank of Maharashtra inaugurates its...